Regence BCBS – Commercial Policy Updates

Changes effective February 1, 2023

Genetic Testing

• Evaluating the Utility of Genetic Panels (#64)

• Genetic Testing for Familial Hypercholesterolemia (#11)

• Targeted Genetic Testing for Selection of Therapy for Non-Small Cell Lung Cancer (NSCLC) (#56)

Laboratory

• Circulating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor Cancers (#46)

• Vitamin D Testing (#52)

Source: https://beonbrand.getbynder.com/m/1cba44648f07f1d4/original/REG-OR-UT-PROVIDER-BULLETIN-February-2023.pdf